Brexu-cel Clears CNS Disease in R/R B-Cell Acute Lymphoblastic Leukemia
February 22nd 2024Findings from a retrospective study demonstrate the feasibility of using brexucabtagene autoleucel to treat patients with relapsed/refractory B-cell acute lymphoblastic leukemia with central nervous system involvement.
Osimertinib After CRT Yields PFS Benefit in EGFR-Mutated NSCLC
February 21st 2024Results from the phase 3 LAURA trial found a statistically significant PFS benefit and a positive trend in OS with osimertinib following chemoradiotherapy in patients with stage III EGFR-mutated non–small cell lung cancer.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.